CN101496884B - Capsule for treating gastric precancerous lesion - Google Patents
Capsule for treating gastric precancerous lesion Download PDFInfo
- Publication number
- CN101496884B CN101496884B CN2008101589427A CN200810158942A CN101496884B CN 101496884 B CN101496884 B CN 101496884B CN 2008101589427 A CN2008101589427 A CN 2008101589427A CN 200810158942 A CN200810158942 A CN 200810158942A CN 101496884 B CN101496884 B CN 101496884B
- Authority
- CN
- China
- Prior art keywords
- grams
- capsule
- precancerous lesion
- stomach cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a capsule for treating stomach cancer precancerous lesion, which is characterized in that the formulation of the capsule comprises the following medicine components in portion by weight: 30 grams of silkworm dropping, 20 grams of astragalus root, 15 grams of ginseng, 12 grams of zedoary, 12 grams of safflower, 15 grams of oldenlandia diffusa, 15 grams of asparagus, 9 grams of rhizoma coptidis, 9 grams of honeysuckle, 9 grams of ageratum, and 12 grams of pinellia tuber. The raw materials in portion by weight are ground into powder, mixed evenly and then encapsulated for taking. The capsule is prepared by using traditional Chinese medicinal materials as raw materials and adopting scientific proportions, has the efficacies of strengthening the spleen and replenishing qi, promoting blood circulation and removing blood stasis, clearing away heat and toxic material, and dispelling dampness and resolving phlegm, can improve the immunologic function of cells and the generation of gastric mucosa cells, can inhibit the movement of bacteria, has obvious effect of treating the stomach cancer precancerous lesion and preventing the generation of stomach cancer without toxic side effects, and is an effective drug for treating the stomach cancer precancerous lesion and preventing the generation of the stomach cancer.
Description
Technical field
The present invention relates to a kind of medicine to precancerous lesion, a kind of specifically capsule of treating gastric precancerous lesion belongs to tcm field.
Background technology
Show according to interrelated data; Chronic atrophic gastritis, intestinal gland metaplasia, enteric epithelium atypical hyperplasia are all classified gastric precancerous lesion as; When chronic atrophic gastritis was followed intestinal gland metaplasia and enteric epithelium atypical hyperplasia, its canceration rate reached 14%, and Chinese scholars is paid much attention to this.Precancerous lesion course that it is generally acknowledged gastric mucosa is " normal mucosa → inflammation → atrophy → intestinalization → dysplasia → gastric cancer ".Precancerous lesion mainly refers to severe dysplasia and the life of imperfection colon typeization, so mucous epitheliumization is given birth to and dysplasia is the emphasis of studying at present.Prevent the key that gastric cancer takes place when impelling the reverse of precancerous lesion, country is " six or five ", " the Seventh Five-Year Plan ", " eight or five " brainstorm subject with the canceration prostatitis.Result of study finds that doctor trained in Western medicine is to this sick efficacious therapy method that lacks, and Chinese medicine has embodied bigger advantage.Gastric precancerous lesion is real to belong to traditional Chinese medical science gastric abscess, feeling of fullness, disease category such as noisy, is cardinal symptom with gastral cavilty distension, stomachache, poor appetite, weak etc., and morbidity is many violates stomach, eating and drinking without temperance by exopathogen; Due to the feelings will internal injury; The course of disease is generally longer, and its pathogenesis mainly is weakness of the spleen and stomach, deficiency of both QI and YIN, companion's qi stagnation blood stasis, turbid damp obstructing in middle-JIAO; The traditional Chinese medical science develops simultaneously spleen and stomach usually, so primary disease is seen weakness of the spleen and stomach or deficiency of both QI and YIN disease more.In recent years, Chinese medicine had played very important effect in the treatment gastric precancerous lesion, obtained some experiences and achievement.But because the prescription that research is adopted has nothing in common with each other, method is different, the curative effect that obtains is also inequality, does not up to the present find ideal medicine always.
Summary of the invention
Technical problem to be solved by this invention provides a kind of capsule of treating gastric precancerous lesion, can improve the regeneration of the immunologic function and the Gastric Mucosal Cells of cell, and can suppress the activity of mushroom, and treatment gastric precancerous lesion and prevention gastric cancer are had positive effect.
In order to achieve the above object, the present invention realizes through following measures: a kind of capsule of treating gastric precancerous lesion is characterized in that: said capsular crude drug is made up of the medicine of following weight parts ratio, Bombyx mori L. 30g; Radix Astragali 20g, Radix Ginseng 15g, Rhizoma Curcumae 12g, Flos Carthami 12g; Hedyotidis Diffusae 15g, Germinatus Phragmitis 15g, Rhizoma Coptidis 9g; Flos Lonicerae 9g, Herba Pogostemonis 9g, Rhizoma Pinelliae 12g.
Below be the further improvement of technique scheme:
With above-mentioned bulk drugs grind into powder, in incapsulating behind the mix homogeneously.
Three months is a course of treatment, and each 4, every day 3 times, warm water takes.
The present invention has invigorating the spleen and benefiting QI, activating blood circulation to dissipate blood stasis, heat-clearing and toxic substances removing, damp eliminating expectorant effect." Bombyx mori L. " wherein is feces that silkworm is discharged in breeding silkworms and the general name of eating surplus residual Mulberry, contains multiple medicinal ingredients such as chlorophyll copper sodium, leaf protein, carotenoid, pectin in the Bombyx mori L..Chlorophyll copper sodium is exactly a kind of of chlorophyll product; Chlorophyll is photosynthetic material base; It is the tie that occurring in nature changes luminous energy into chemical energy; It has very important meaning to tellurian living matter, after the chlorophyll product is absorbed by the body, body and cell is had activation and the effect that enhances metabolism.Have and report that chlorophyll copper sodium has the synthetic effect of hepatoprotective, promotion wound healing, inhibition cell carcinogenesis, cholesterol reducing, blood sugar lowering, antiallergic, bacteriostasis, and deodorization and promotion hemoglobin.Hepatitis, gastric ulcer, duodenal ulcer, oral ulcer, acute pancreatitis, chronic nephritis etc. have been used to treat clinically.At present, " liver is precious " on the market, " weisen U ", " stomach is sweet green ", " treasured of entering a higher school ", " green forint ointment " etc. all are the chlorophyll copper sodium salt prefs.The metabolism of advancing by leaps and bounds of chlorophyll copper sodium, active cell growth, inhibition cell carcinogenesis in the main development and use of this research Bombyx mori L.; Eliminate the effect that the cell inflammatory changes; The Gastric Mucosal Cells of atrophy, impaired pancreatic cell and the Insulin receptor INSR cell of function reduction there are maintenance and regenerated effect; The gastric mucosa of improvement and the effect of pancreas inner blood circulation are arranged simultaneously, eliminate the effect that the cell inflammatory changes in addition, this is the main mechanism that promotes gastric mucosa reparation, blood sugar lowering; The Radix Astragali has the effect of invigorating the spleen and benefiting QI; Can regulate nerve balance, excited antepituitary, promote the adrenal hormone secretion to increase; Thereby the content of immunoglobulin in the increase body promotes lymphocyte transformation, strengthens reticuloendothelial system phagocytic activity; Eliminate carcinogenic free radical, impel effects such as cancerous cell reverse; Radix Ginseng has the effect of invigorating the spleen and benefiting QI; Rhizoma Curcumae, Flos Carthami have the effect of activating blood circulation to dissipate blood stasis, heat-clearing and toxic substances removing, can improve the local blood circulation state, promote the irritability of mucosa regeneration, increase islet cell function and Insulin receptor INSR; Herba Pogostemonis, the Rhizoma Pinelliae have damp eliminating expectorant effect; Rhizoma Coptidis, Flos Lonicerae have the effect of heat-clearing and toxic substances removing; The immunity of Hedyotidis Diffusae ability enhancing body suppresses the growth of tumor cell, has the effect of heat-clearing and toxic substances removing; Contain in the Germinatus Phragmitis that more asparagine, aspartic acid and other are multiple ladles out body Saponin material, but cancer-resisting is the primary raw material of cancer therapy drug.
The present invention is a raw material with the Chinese medicine material; The employing scientific matching is prepared from; Have invigorating the spleen and benefiting QI, activating blood circulation to dissipate blood stasis, heat-clearing and toxic substances removing, damp eliminating expectorant effect, can improve the regeneration of the immunologic function and the Gastric Mucosal Cells of cell, and can suppress the activity of mushroom; Treatment gastric precancerous lesion and prevention gastric cancer are had positive effect, and its beneficial effect can show following several respects:
1, capsule of the present invention can effectively improve chronic atrophic gastritis patient's clinical symptoms;
2, take behind the capsule for treating of the present invention under the gastroscope gastric mucosa sign of atrophy and take a turn for the better, body of gland increases under the pathology, and mucosa thickens;
3, capsule of the present invention all has tangible curative effect to due to weakness of spleen and stomach and type of deficiency of both QI and YIN chronic atrophic gastritis, and the former effect is more remarkable;
4, promote chronic atrophic gastritis gastric mucosa hypertrophy, improve the gastric mucosa blood flow;
5, the adjustment body's immunity is arranged, correct the effect of anemia and blood sugar lowering;
6, the effect of anti-helicobacter pylori is arranged;
7, the main component Bombyx mori L. in the prescription has the chronic atrophic gastritis of promotion Gastric Mucosal Cells to reverse the effect that stops gastric cancer to take place.
Below in conjunction with the specific embodiment technical scheme of the present invention is further explained:
The specific embodiment
Embodiment, we adopt the present invention as medicine year March in March, 2002-2007, choose 128 routine sufferers and are made as the treatment group and treat, and choose 128 routine sufferers simultaneously and are made as the sucralfate matched group.All sufferer is all made a definite diagnosis through scope and gastric mucosa living tissue pathological examination, and therapeutic effect is main foundation with pathological change before and after the treatment.Withdraw other drug during the treatment, 3 months was 1 course of treatment, serve on 2 courses of treatment, during diet and in proper working order.
The treatment group adopts following therapeutic scheme: a kind of capsule of treating gastric precancerous lesion, and said capsular crude drug is made up of the medicine of following weight parts ratio, Bombyx mori L. 30g, Radix Astragali 20g, Radix Ginseng 15g; Rhizoma Curcumae 12g, Flos Carthami 12g, Hedyotidis Diffusae 15g, Germinatus Phragmitis 15g, Rhizoma Coptidis 9g; Flos Lonicerae 9g, Herba Pogostemonis 9g, Rhizoma Pinelliae 12g is with above-mentioned bulk drugs grind into powder; In incapsulating behind the mix homogeneously, each 4, every day 3 times, warm water takes.
Matched group adopts following therapeutic scheme: take the thiosugar aluminium flake, and each 4, every day 3 times.
Therapeutic outcome
Table 1 treatment preceding and treatment back treatment group and matched group disease situation of change
Can find out that by table 1 84.62%～93.87%, and matched group explains that 44.44%～78.13% the therapeutic scheme of treatment group is superior to the therapeutic scheme of matched group at the effective percentage that improves treatment group cardinal symptom aspect the symptom.
Table 2 liang group total effects relatively
| Divide into groups | The example number | Produce effects | Take a turn for the better | Invalid | Total effective rate |
| The treatment group | 128 | 32(25) | 58(58.58) | 38(29.69) | 70.31 |
| Matched group | 128 | 12(9.37) | 34(26.56) | 82(64.06) | 35.94 |
Can be found out that by table 2 the total effects effective percentage of treatment group and matched group is respectively 70.31% and 35.94%, the treatment group is superior to matched group.
Table 3 treatment component type curative effect relatively
| Divide into groups | The example number | Produce effects | Take a turn for the better | Invalid | Total effective rate |
| Due to weakness of spleen and stomach | 90 | 30(33.33) | 42(46.67) | 18(20) | 80 |
| Type of deficiency of both QI and YIN | 38 | 3(7.89) | 14(36.84) | 21(55.26) | 44.73 |
Can be found out that by table 3 total effective rate of treatment due to weakness of spleen and stomach is 80% in the treatment of treatment component type, the total effective rate of treatment type of deficiency of both QI and YIN is 44.73%
Interpretation of result
The treatment group is compared with matched group, and treatment group treatment symptom effective percentage is 84.62%～93.87%, and treatment of control group symptom effective percentage is that 44.44%～78.13%, two groups of total effects effective percentage are respectively 70.31% and 35.94%; The total effective rate of treatment group due to weakness of spleen and stomach and type of deficiency of both QI and YIN is 80% and 44.73%; Capsule of the present invention can improve patient's hematochrome, cellular immune function and plasma cAMP content, and effectively suppresses helicobacter pylori and promote the regenerated effect of Gastric Mucosal Cells.Therefore, no matter capsule for treating gastric precancerous lesion of the present invention is from improving symptom, eliminate or alleviate mucosa infection; Promote mucosal tissue to reverse curative effect is preferably all arranged; And obviously be superior to matched group, and helicobacter pylori is had certain inhibitory or killing effect, in therapeutic process, do not find toxic and side effects.So capsule of the present invention is the active drug that treatment gastric precancerous lesion, prevention gastric cancer take place, and can apply.
Claims (2)
1. capsule of treating gastric precancerous lesion, it is characterized in that: said capsular crude drug is made up of the medicine of following weight parts ratio: Bombyx mori L. 30g, Radix Astragali 20g, Radix Ginseng 15g; Rhizoma Curcumae 12g, Flos Carthami 12g, Hedyotidis Diffusae 15g, Germinatus Phragmitis 15g; Rhizoma Coptidis 9g, Flos Lonicerae 9g, Herba Pogostemonis 9g, Rhizoma Pinelliae 12g.
2. a kind of capsule of treating gastric precancerous lesion according to claim 1 is characterized in that: with above-mentioned bulk drugs grind into powder, in incapsulating behind the mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101589427A CN101496884B (en) | 2008-11-21 | 2008-11-21 | Capsule for treating gastric precancerous lesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101589427A CN101496884B (en) | 2008-11-21 | 2008-11-21 | Capsule for treating gastric precancerous lesion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101496884A CN101496884A (en) | 2009-08-05 |
| CN101496884B true CN101496884B (en) | 2012-07-25 |
Family
ID=40944293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101589427A Expired - Fee Related CN101496884B (en) | 2008-11-21 | 2008-11-21 | Capsule for treating gastric precancerous lesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101496884B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349884B (en) * | 2011-08-26 | 2013-04-03 | 东莞广州中医药大学中医药数理工程研究院 | Application of patchouli alcohol in preparation of helicobacter pylori resistant medicament |
| CN103751347B (en) * | 2014-02-08 | 2015-09-02 | 王秀勤 | A kind of Chinese medicine composition for the treatment of duodenal ulcer |
| CN105833115B (en) * | 2016-04-29 | 2020-02-14 | 杜艳茹 | Traditional Chinese medicine for treating gastric precancerous lesion |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1475241A (en) * | 2002-08-15 | 2004-02-18 | 孟宪义 | Chinese medicine for treating stomach disease |
| CN101085328A (en) * | 2007-06-20 | 2007-12-12 | 济南新境界企业管理咨询有限公司 | Oral administration traditional Chinese medicine composition for curing chronic gastritis |
-
2008
- 2008-11-21 CN CN2008101589427A patent/CN101496884B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1475241A (en) * | 2002-08-15 | 2004-02-18 | 孟宪义 | Chinese medicine for treating stomach disease |
| CN101085328A (en) * | 2007-06-20 | 2007-12-12 | 济南新境界企业管理咨询有限公司 | Oral administration traditional Chinese medicine composition for curing chronic gastritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101496884A (en) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101874874B (en) | Chinese medicinal preparation for treating helicobacter pylori concerned chronic gastritis and preparation method thereof | |
| CN102188614A (en) | Capsule for gastric ulcer | |
| CN101496884B (en) | Capsule for treating gastric precancerous lesion | |
| CN1768844A (en) | Gastropathy dedicated Chinese medicine | |
| CN102631615B (en) | Traditional Chinese medicine powder for treating stomach and duodenal ulcer | |
| CN102139058B (en) | Traditional Chinese medicine for treating stomach diseases | |
| CN1233354C (en) | Chinese medicine preparation for treating carcinoma of esophagus | |
| CN102145096B (en) | Decoction for treating helicobacter pylori-associated gastritis | |
| CN1201772C (en) | Chinese medicine for treating chronic atrophic gastritis | |
| CN102038822B (en) | Compound infusion for treating gastrointestinal diseases | |
| CN101954060A (en) | Medicament for treating stomach disease | |
| CN101085197A (en) | Vein relaxing capsule for treating chronic pharyngitis | |
| CN1330361C (en) | Chinese medicine special for treating chronic atrophic gastritis | |
| CN103816265B (en) | A kind ofly be used for the treatment of medicine of having loose bowels and preparation method thereof | |
| CN101019938B (en) | Chinese medicine for treating enteritis and colitis and its preparation method | |
| CN101670046A (en) | Chinese medicinal composition for gastritis and esophagitis and preparation process thereof | |
| CN1217688C (en) | Medicine for treating chronic gastritis and preparing process thereof | |
| CN1457805A (en) | Chinese medicine preparation for curing eophagus cancer | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN1695696A (en) | Wasting-thirst capsule of root powder for treating diabetes | |
| CN1583032A (en) | Chinese medicine preparation for stomach diseases | |
| CN104800483A (en) | Traditional Chinese medicine composition for treating psychogenic diseases and preparation method thereof | |
| CN112516241A (en) | Pharmaceutical composition for treating nasopharyngeal carcinoma and application thereof | |
| CN101342347A (en) | Ulcer powder for treating gastropathy | |
| CN108524893A (en) | A kind of drug and preparation method thereof for treating abdominal distension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120725 Termination date: 20141121 |
|
| EXPY | Termination of patent right or utility model |